AccuMed and Biokit in joint venture:
This article was originally published in Clinica
AccuMed International (US) and Biokit (Spain) have signed a joint venture agreement to develop a low-cost, automatic Kirby Bauer reader. Biokit will license software to AccuMed as part of a worldwide technology agreement. The deal "will result in the earlier development of our unique proprietary system for the $250 million market", says Peter Gombrich, CEO of AccuMed. Kirby Bauer systems test microbiology samples to identify the most suitable type and concentration of antibiotics. Terms of the deal were not disclosed.
You may also be interested in...
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.